HILLEMAN JERYL L 4

What Happened Jeryl L. Hilleman, a director of NovoCure Ltd (NVCR), was granted two equity awards on 2026-06-03: 11,610 restricted stock units (RSUs) and a derivative award covering 16,999 shares (options to buy ordinary shares). Both awards were reported as acquired at $0.00 per share in the Form 4 filing, meaning Hilleman received equity awards rather than purchasing shares with cash.

Key Details

• Transaction date: 2026-06-03; Form 4 filed 2026-06-05.
• Grants: 11,610 RSUs (acquired @ $0.00) and 16,999 derivative shares (acquired @ $0.00).
• Vesting/Exercise schedule:
  • RSUs (F1): scheduled to vest 100% on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company’s 2027 annual general meeting.
  • Options/derivative award (F2): will fully vest and become exercisable on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company’s 2027 annual general meeting.
• Shares owned after the transaction: not specified in the excerpt of the filing provided.
• Filing timeliness: Form 4 was filed two days after the transaction date (2026-06-05 for a 2026-06-03 transaction), which is typical for timely insider reports.

Context

• These transactions are grants/awards (code A) — not open-market purchases or sales — so they reflect compensation or board-related equity awards rather than the insider buying shares with personal cash.
• The derivative award represents options or similar rights to acquire ordinary shares under the company plan; they do not represent exercised or sold shares at this time.
• Such awards are common for directors as part of compensation; they do not by themselves indicate buying or selling sentiment.